GlassScriptPhysician profile
Amanda Lydic Cook
NPI 1912999822
$3,608.27
in general payments reported to CMS, 2019-2025
23 companies · $616 in 2025
The $616 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $542 · 2020: $725 · 2021: $583 · 2022: $297 · 2023: $365 · 2024: $480 · 2025: $616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,462.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,461.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $887.76 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $610.41 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $586.52 | 2019-2021 | |
| Alcon Vision LLC | $361.07 | 2019-2025 | Clareon, Argos, Rocklatan |
| Abbvie INC. | $305.73 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Novartis Pharmaceuticals Corporation | $132.10 | 2019-2023 | |
| Tarsus Pharmaceuticals, INC. | $116.71 | 2024-2025 | Xdemvy |
| Glaukos Corporation | $110.93 | 2024-2025 | Istent Infinite, Idose, Istent Trabecular Micro-Bypass System Model Is3 |
| Sun Pharmaceutical Industries INC. | $67.34 | 2019-2023 | Cequa |
| Biotissue Holdings INC. | $63.47 | 2019-2022 | |
| Dompe US, INC. | $54.17 | 2019-2025 | Oxervate |
| Thea Pharma INC. | $44.33 | 2024-2025 | Iyuzeh |
| Harrow Eye, LLC | $35.47 | 2024-2025 | Vevye |
| Medline Industries LP | $34.05 | 2025 | |
| Eyevance Pharmaceuticals LLC | $30.65 | 2020-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $25.58 | 2022 | |
| Dexcom, INC. | $25.06 | 2024 | Dexcom G6 Transmitter |
| Shire North American Group INC | $23.93 | 2019 | |
| Ivantis, INC | $23.13 | 2020 | |
| Aerie Pharmaceuticals, INC. | $20.34 | 2020 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Horizon Therapeutics Plc | $18.13 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $11.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Cook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.